Your browser doesn't support javascript.
loading
What is the role of complement in bystander hemolysis? Old concept, new insights.
Evangelidis, Paschalis; Evangelidis, Nikolaos; Vlachaki, Efthymia; Gavriilaki, Eleni.
Affiliation
  • Evangelidis P; Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Evangelidis N; Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Vlachaki E; Adult Thalassemia Unit, 2nd Department of Internal Medicine, Aristotle University of Thessaloniki, Hippocration General Hospital, Thessaloniki, Greece.
  • Gavriilaki E; Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Expert Rev Hematol ; 17(4-5): 107-116, 2024.
Article de En | MEDLINE | ID: mdl-38708453
ABSTRACT

INTRODUCTION:

Bystander hemolysis occurs when antigen-negative red blood cells (RBCs) are lysed by the complement system. Many clinical entities including passenger lymphocyte syndrome, hyperhemolysis following blood transfusion, and paroxysmal nocturnal hemoglobinuria are complicated by bystander hemolysis. AREAS COVERED The review provides data about the role of the complement system in the pathogenesis of bystander hemolysis. Moreover, future perspectives on the understanding and management of this syndrome are described. EXPERT OPINION Complement system can be activated via classical, alternative, and lectin pathways. Classical pathway activation is mediated by antigen-antibody (autoantibodies and alloantibodies against autologous RBCs, infectious agents) complexes. Alternative pathway initiation is triggered by heme, RBC microvesicles, and endothelial injury that is a result of intravascular hemolysis. Thus, C5b is formed, binds with C6-C9 compomers, and MAC (C5b-9) is formulated in bystander RBCs membranes, leading to cell lysis. Intravascular hemolysis, results in activation of the alternative pathway, establishing a vicious cycle between complement activation and bystander hemolysis. C5 inhibitors have been used effectively in patients with hyperhemolysis syndrome and other entities characterized by bystander hemolysis.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protéines du système du complément / Activation du complément / Érythrocytes / Hémolyse Limites: Humans Langue: En Journal: Expert Rev Hematol Sujet du journal: HEMATOLOGIA Année: 2024 Type de document: Article Pays d'affiliation: Grèce Pays de publication: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protéines du système du complément / Activation du complément / Érythrocytes / Hémolyse Limites: Humans Langue: En Journal: Expert Rev Hematol Sujet du journal: HEMATOLOGIA Année: 2024 Type de document: Article Pays d'affiliation: Grèce Pays de publication: Royaume-Uni